The Cancer Genome Atlas

Use the filters below to select your cohort
Patient Definition Age Smoking_y Alcohol history Gender Stage TNM stage Grade KRAS variant Moffit subtype Collisson subtype Bailey subtype Diabetes diagnosis indicator Diabetes diagnosis days to History chronic pancreatitis History chronic pancreatitis days to Family history cancer indicator Family history cancer type
TCGA-2J-AAB1-01A PDAC 66 26 yes Male IIB T3N1M0 G3 G12D,G12R Classical Classical Progenitor NO NA NO NA NO NA
TCGA-2J-AAB4-01A PDAC 49 NA no Male IIB T2N1M0 G2 G12V Classical Classical Progenitor NO NA YES -292 Unknown NA
TCGA-2J-AAB6-01A PDAC 76 NA no Male IIA T3N0M0 G2 G12V Basal QM Squamous NO NA NO NA Unknown NA
TCGA-2J-AAB8-01A PDAC 71 NA no Male IIB T3N1M0 G3 G12R Classical Classical Progenitor NO NA NO NA Unknown NA
TCGA-2J-AAB9-01A PDAC 71 NA yes Female IIB T3N1M0 G1 G12D Basal Exocrine ADEX NO NA NO NA YES Pancreas|Other
TCGA-2J-AABA-01A PDAC 55 NA no Male IIB T3N1M0 G2 Wild type Classical Classical Progenitor NO NA YES -18029 Unknown NA
TCGA-2J-AABE-01A PDAC 74 10 yes Male IIA T3N0M0 G2 G12R Basal Classical Progenitor YES -9 NO NA NO NA
TCGA-2J-AABF-01A PDAC 74 5 yes Male IIB T3N1M0 G3 G12D Classical Exocrine Progenitor NO NA NO NA YES Other
TCGA-2J-AABH-01A PDAC 61 NA no Male IIA T3N0M0 G3 G12V,G12S Classical Exocrine Progenitor NO NA NO NA YES Other
TCGA-2J-AABI-01A PDAC 56 31 yes Female IIA T3N0M0 G3 G12R Basal QM Squamous NO NA YES -46 NO NA
TCGA-2J-AABK-01A PDAC 72 NA no Male IIB T3N1M0 G2 G12V Classical Exocrine Progenitor NO NA NO NA Unknown NA
TCGA-2J-AABO-01A PDAC 43 10 no Male IIB T3N1M0 G2 G12V Basal Exocrine ADEX NO NA NO NA YES Other
TCGA-2J-AABP-01A PDAC 59 NA yes Female IIB T3N1M0 G4 Wild type NA NA NA NO NA NO NA YES Other
TCGA-2J-AABR-01A PDAC 61 NA no Female IIA T3N0M0 G3 G12V Basal Exocrine ADEX NO NA NO NA Unknown NA
TCGA-2J-AABT-01A PDAC 72 NA yes Female IIB T3N1M0 G2 G12R Classical Classical Immunogenic YES -79 YES -80 NO NA
TCGA-2J-AABU-01A PDAC 57 NA yes Male IIB T3N1M0 G3 G12R Basal QM Squamous NO NA NO NA NO NA
TCGA-2J-AABV-01A PDAC 74 NA no Male IIB T3N1M0 G4 G12V Classical Exocrine ADEX NO NA NO NA Unknown NA
TCGA-2L-AAQA-01A PDAC 77 NA yes Male IIB T3N1MX G2 G12V Classical Classical Progenitor NO NA NO NA Unknown NA
TCGA-2L-AAQE-01A PDAC 56 NA yes Male IIB T3N1M0 G2 G12D Basal Classical Squamous YES -171 YES -171 Unknown NA
TCGA-2L-AAQI-01A PDAC 67 NA yes Male IIB T3N1MX G3 G12V Basal Exocrine Progenitor Unknown NA YES -50 NO NA
TCGA-2L-AAQJ-01A PDAC 50 NA yes Female III T4N0MX G2 G12D Classical Classical Progenitor NO NA NO NA Unknown NA
TCGA-2L-AAQL-01A PDAC 82 NA yes Male IIB T3N1MX G3 Q61R Classical Exocrine Progenitor NO NA NO NA NO NA
TCGA-2L-AAQM-01A PDAC 53 NA yes Male IIB T3N1MX G1 Wild type NA NA NA Unknown NA NO NA Unknown NA
TCGA-3A-A9I5-01A PDAC 58 NA no Male NA N0MX G1 Wild type Classical Exocrine ADEX NO NA NO NA YES Other
TCGA-3A-A9I7-01A PDAC 46 NA yes Male IIB T3N1MX G2 G12D Classical Exocrine Immunogenic NO NA NO NA NO NA
TCGA-3A-A9I9-01A PDAC 68 NA yes Male IIA T3N0MX G2 G12R Classical Exocrine ADEX NO NA NO NA YES Other
TCGA-3A-A9IB-01A PDAC 69 20 no Female IIB T3N1MX G3 G12D Basal QM Squamous YES NA YES 1 NO NA
TCGA-3A-A9IC-01A PDAC 61 NA yes Female IIB T3N1MX G2 G12R Classical QM Squamous NO NA YES NA YES Other
TCGA-3A-A9IH-01A PDAC 66 NA yes Female IA T1N0MX G2 G12R Basal Classical Progenitor NO NA YES NA NO NA
TCGA-3A-A9IJ-01A PDAC 65 30 no Male IB T2N0MX G1 Wild type NA NA NA NO NA NO NA NO NA
TCGA-3A-A9IL-01A PDAC 40 NA no Female I T1MX G1 Wild type NA NA NA NO NA NO NA NO NA
TCGA-3A-A9IN-01A PDAC 62 NA yes Female IB T2NXMX G2 Wild type NA NA NA NO NA NO NA YES Other
TCGA-3A-A9IO-01A PDAC 56 NA yes Male NA TXNXMX G1 Wild type NA NA NA YES NA NO NA NO NA
TCGA-3A-A9IR-01A PDAC 64 15 yes Female IB T2N0MX G1 Wild type NA NA NA NO NA NO NA YES Other
TCGA-3A-A9IS-01A PDAC 67 NA no Male IB T2N0MX G1 Wild type NA NA NA NO NA NO NA NO NA
TCGA-3A-A9IU-01A PDAC 66 NA yes Male IIB T3N1MX G3 G12D Basal Exocrine Squamous NO NA NO NA NO NA
TCGA-3A-A9IV-01A PDAC 60 NA yes Female IB T2N0MX G1 Wild type NA NA NA NO NA NO NA YES Other
TCGA-3A-A9IX-01A PDAC 40 22 yes Male IA T1N0MX G2 G12D Basal Exocrine ADEX YES -50 NO NA NO NA
TCGA-3A-A9IZ-01A PDAC 47 NA no Male IIB T3N1MX G2 G12D Basal Classical Squamous NO NA NO NA NO NA
TCGA-3A-A9J0-01A PDAC 75 NA no Male IIB T3N1MX G2 Wild type Classical Classical Progenitor NO NA NO NA NO NA
TCGA-3E-AAAY-01A PDAC 68 NA yes Male IIB T3N1MX G3 G12D Classical Exocrine ADEX NO NA NO NA NA NA
TCGA-3E-AAAZ-01A PDAC 72 NA NA Male IIA T3N0MX G2 G12V Classical Exocrine Progenitor NA NA NA NA NA NA
TCGA-F2-6879-01A PDAC 57 NA yes Male IIB T3N1M0 G2 G12V Classical Classical Progenitor NO NA NO NA YES Pancreas
TCGA-F2-6880-01A PDAC 71 NA yes Male IIB T3N1M0 G1 Wild type NA NA NA YES NA NO NA NO NA
TCGA-F2-7273-01A PDAC 55 NA no Male IIB T3N1M0 G3 Wild type NA NA NA NO NA NO NA NO NA
TCGA-F2-7276-01A PDAC 65 NA no Male IIB T3N1M0 G1 Wild type NA NA NA YES -54 NO NA YES Other
TCGA-F2-A44G-01A PDAC 80 NA yes Female IIB T3N1M0 G2 G12D Classical Classical Progenitor NO NA NO NA NO NA
TCGA-F2-A44H-01A PDAC 66 NA no Male IIA T3N0M0 G2 Wild type Classical Exocrine ADEX YES NA NO NA YES Other
TCGA-F2-A7TX-01A PDAC 77 NA yes Male IIB T3N1M0 G3 G12D Basal Exocrine ADEX YES NA NO NA YES Breast
TCGA-F2-A8YN-01A PDAC 77 NA yes Male IIA T3N0M0 G2 G12R Basal Classical Progenitor YES NA NO NA YES Other
TCGA-FB-A4P5-01A PDAC 70 40 no Female IIB T3N1MX G2 G12D Basal Exocrine ADEX NO NA NO NA YES Other
TCGA-FB-A4P6-01A PDAC 55 25 yes Male IIB T3N1MX G1 G12V Classical Exocrine ADEX NO NA NO NA NO NA
TCGA-FB-A545-01A PDAC 73 NA no Female IIB T3N1M0 G2 G12V Basal QM Squamous NO NA NA NA YES Melanoma
TCGA-FB-A5VM-01A PDAC 75 47 yes Male IB T2N0M0 G3 Q61H Basal QM Squamous YES NA NO NA NO NA
TCGA-FB-A78T-01A PDAC 72 20 no Female IIB T3N1M0 G2 G12A,G13C Classical Exocrine Progenitor NO NA Unknown NA YES Other
TCGA-FB-A7DR-01A PDAC 48 NA yes Male IIA T3NXM0 G2 Wild type NA NA NA NO NA NA NA NO NA
TCGA-FB-AAPP-01A PDAC 72 NA yes Male IIB T3N1MX G3 Wild type NA NA NA NO NA NO NA YES Pancreas
TCGA-FB-AAPQ-01A PDAC 66 25 no Male IIB T3N1MX G2 G12D Classical Classical Progenitor YES NA NO NA Unknown NA
TCGA-FB-AAPS-01A PDAC 63 10 no Female IIB T2N1MX G2 G12D Basal Exocrine Immunogenic NO NA NO NA Unknown NA
TCGA-FB-AAPU-01A PDAC 41 NA yes Female IIA T3N0MX G2 G12R Classical Classical Progenitor NO NA YES -71 Unknown NA
TCGA-FB-AAPY-01A PDAC 71 25 yes Male IIB T2N1MX G2 G12D Classical Exocrine Progenitor YES -9070 Unknown NA YES Breast
TCGA-FB-AAPZ-01A PDAC 54 NA no Male IIB T2N1MX G3 G12R Basal Exocrine Squamous NO NA NO NA YES Breast
TCGA-FB-AAQ0-01A PDAC 68 NA no Male IIA T3N0MX G3 G12R Classical Classical Progenitor YES 20 NO NA YES Pancreas
TCGA-FB-AAQ1-01A PDAC 50 NA no Male IIB T3N1MX G2 G12D Basal Exocrine ADEX NO NA NO NA Unknown NA
TCGA-FB-AAQ2-01A PDAC 81 NA yes Female IIB T3N1MX G3 G12D Basal QM Squamous YES -198 NO NA NO NA
TCGA-FB-AAQ3-01A PDAC 66 NA yes Female IIB T3N1MX G2 G12D Classical Exocrine Progenitor NO NA NO NA YES Breast
TCGA-FB-AAQ6-01A PDAC 86 NA yes Male IA T1N0MX G2 G12V Classical Classical Progenitor NO NA NO NA Unknown NA
TCGA-H6-8124-01A PDAC 57 7 yes Female IIB T3N1M0 G3 G12V Basal QM Squamous NO NA NO NA YES Other
TCGA-H6-8124-11A Normal 57 7 yes Female IIB T3N1M0 G3 NA NA NA NA NO NA NO NA YES Other
TCGA-H6-A45N-01A PDAC 89 NA yes Female IIB T3N1MX G3 G12V Classical Exocrine ADEX NO NA NO NA YES NA
TCGA-H6-A45N-11A Normal 89 NA yes Female IIB T3N1MX G3 NA NA NA NA NO NA NO NA YES NA
TCGA-H8-A6C1-01A PDAC 54 30 yes Male IIA T3N0MX G2 Wild type NA NA NA NO NA NO NA YES Other
TCGA-HV-A5A3-01A PDAC 51 NA yes Male IIA T3NXMX G2 G12D Basal Classical Squamous NO NA NO NA NA NA
TCGA-HV-A5A3-11A Normal 51 NA yes Male IIA T3NXMX G2 NA NA NA NA NO NA NO NA NA NA
TCGA-HV-A5A4-01A PDAC 72 NA no Female IIA T3N0MX G2 G12V Classical Classical Progenitor NO NA NO NA NA NA
TCGA-HV-A5A5-01A PDAC 61 NA yes Female IIB T3N1M0 G2 G12D Classical Exocrine ADEX NO NA NO NA NA NA
TCGA-HV-A5A6-01A PDAC 66 NA NA Female IIB T3N1bM0 G1 G12D Classical Classical Squamous NO NA NO NA NA NA
TCGA-HV-A7OL-01A PDAC 71 NA yes Male IIA T3N0MX G2 G12D Classical Classical Progenitor YES NA NO NA NA NA
TCGA-HV-A7OP-01A PDAC 72 NA yes Male IIB T3N1M0 GX Wild type NA NA NA NO NA NO NA NO NA
TCGA-HV-AA8V-01A PDAC 50 NA yes Male IIB T3N1MX G3 G12V Basal Classical Squamous NO NA NO NA NA NA
TCGA-HV-AA8X-01A PDAC 76 NA no Female IIB T2N1MX G2 G12D Classical Classical Progenitor NO NA NO NA NA NA
TCGA-HZ-7289-01A PDAC 77 NA no Male IIB T3N1MX G1 Wild type NA NA NA Unknown NA Unknown NA Unknown NA
TCGA-HZ-7918-01A PDAC 73 NA no Male IIB T3N1M0 G3 Wild type NA NA NA Unknown NA Unknown NA Unknown NA
TCGA-HZ-7919-01A PDAC 52 NA no Female IIB T3N1M0 G2 G12R Classical Classical Progenitor Unknown NA Unknown NA Unknown NA
TCGA-HZ-7920-01A PDAC 72 NA no Male IB T2N0MX G2 Wild type NA NA NA Unknown NA Unknown NA Unknown NA
TCGA-HZ-7922-01A PDAC 61 NA no Female IIB T3N1MX G1 Q61H Classical Exocrine ADEX Unknown NA Unknown NA Unknown NA
TCGA-HZ-7923-01A PDAC 65 NA NA Male IIA T3N0MX G2 Wild type NA NA NA NA NA NA NA NA NA
TCGA-HZ-7924-01A PDAC 61 NA no Female IIA T3N0MX G2 Wild type NA NA NA Unknown NA Unknown NA Unknown NA
TCGA-HZ-7925-01A PDAC 66 NA no Male IIB T3N1MX G2 G12V Basal QM Immunogenic Unknown NA Unknown NA Unknown NA
TCGA-HZ-7926-01A PDAC 58 NA no Male IIB T3N1MX G1 G12D Classical Exocrine Progenitor Unknown NA Unknown NA Unknown NA
TCGA-HZ-8001-01A PDAC 69 NA NA Male III T4N0MX G2 G12V Basal QM Immunogenic NA NA NA NA NA NA
TCGA-HZ-8002-01A PDAC 61 NA NA Male IIB T3N1MX G2 G12D Basal Exocrine ADEX NA NA NA NA NA NA
TCGA-HZ-8003-01A PDAC 65 NA NA Female IIB T3N1MX G2 G12R Classical Exocrine ADEX NA NA NA NA NA NA
TCGA-HZ-8005-01A PDAC 81 NA NA Male IIB T3N1MX G3 Q61H Basal QM Squamous Unknown NA Unknown NA Unknown NA
TCGA-HZ-8315-01A PDAC 54 NA NA Female IIA T3N0MX G2 G12D Basal Exocrine ADEX Unknown NA Unknown NA Unknown NA
TCGA-HZ-8317-01A PDAC 69 NA no Female IIB T3N1MX G1 Wild type Classical Exocrine ADEX Unknown NA Unknown NA Unknown NA
TCGA-HZ-8519-01A PDAC 74 NA no Male IA T1N0MX G3 G12D Classical Exocrine Immunogenic Unknown NA Unknown NA Unknown NA
TCGA-HZ-8636-01A PDAC 59 NA no Female IV T3N0M1 G3 G12V Classical QM Immunogenic Unknown NA Unknown NA Unknown NA
TCGA-HZ-8637-01A PDAC 77 NA no Female IIB T3N1MX G3 G12V Classical QM Immunogenic Unknown NA Unknown NA Unknown NA
TCGA-HZ-8638-01A PDAC 84 NA no Female IA T1N0MX GX Wild type NA NA NA Unknown NA Unknown NA Unknown NA
TCGA-HZ-A49G-01A PDAC 59 NA no Female IIB T2N1MX G2 G12D Classical Exocrine ADEX Unknown NA Unknown NA Unknown NA
TCGA-HZ-A49H-01A PDAC 68 NA no Female IIB T3N1MX G2 G12V Classical Exocrine ADEX Unknown NA Unknown NA Unknown NA
TCGA-HZ-A49I-01A PDAC 78 NA no Male IIB T3N1MX G2 G12D Classical Classical Progenitor Unknown NA Unknown NA Unknown NA
TCGA-HZ-A4BH-01A PDAC 76 NA no Male IIB T3N1bMX G3 G12D Basal Classical Immunogenic Unknown NA Unknown NA Unknown NA
TCGA-HZ-A4BK-01A PDAC 73 NA no Male IIB T3N1MX G3 G12D Classical Exocrine Progenitor Unknown NA Unknown NA Unknown NA
TCGA-HZ-A77O-01A PDAC 78 NA no Female IIB T2N1MX G2 G12V Basal Exocrine ADEX NO NA NO NA NO NA
TCGA-HZ-A77P-01A PDAC 78 NA no Male IIB T3N1MX G1 G12V Classical Exocrine ADEX NO NA NO NA YES Other
TCGA-HZ-A77Q-01A PDAC 56 NA no Female IIB T3N1MX G2 G12R Basal QM Immunogenic YES NA NO NA NO NA
TCGA-HZ-A8P0-01A PDAC 76 20 yes Male IIB T3N1MX G1 Q61H Classical Exocrine ADEX NO NA NO NA YES Other
TCGA-HZ-A8P1-01A PDAC 81 15 no Male IB T2N0MX G1 G12D Classical Classical Progenitor NO NA NO NA NO NA
TCGA-HZ-A9TJ-01A PDAC 71 NA no Male IV T3N0M1 G2 G12V Classical Classical Progenitor Unknown NA Unknown NA Unknown NA
TCGA-IB-7644-01A PDAC 66 NA yes Female IV T3N1M1 G2 G12V Classical Classical Progenitor YES NA NO NA NO NA
TCGA-IB-7645-01A PDAC 44 NA NA Female IIB T3N1M0 G1 G12V Classical QM Immunogenic NO NA NO NA NO NA
TCGA-IB-7646-01A PDAC 61 NA yes Male IIB T3N1M0 G2 G12D Basal QM Squamous NO NA NO NA NO NA
TCGA-IB-7647-01A PDAC 42 NA yes Male IIB T3N1M0 G2 G12V Classical Classical Immunogenic NO NA NO NA YES Other
TCGA-IB-7649-01A PDAC 73 NA no Female IIB T3N1M0 G2 Q61H Classical Exocrine ADEX NO NA NO NA Unknown NA
TCGA-IB-7651-01A PDAC 65 NA yes Female IIB T3N1M0 G2 G12D Classical Exocrine Immunogenic YES 504 NO NA YES Breast
TCGA-IB-7652-01A PDAC 50 NA yes Female IIB T3N1M0 G2 G12R Classical Exocrine ADEX NO NA NO NA NO NA
TCGA-IB-7654-01A PDAC 80 NA no Male IIB T2N1M0 G2 Wild type NA NA NA NO NA NO NA Unknown NA
TCGA-IB-7885-01A PDAC 78 20 yes Female IIB T3N1M0 G2 G12V Basal QM Squamous NO NA NO NA YES Other
TCGA-IB-7886-01A PDAC 80 NA yes Male IIB T3N1M0 G3 G12C Classical Classical Progenitor NO NA NO NA NO NA
TCGA-IB-7887-01A PDAC 63 NA no Female IIB T3N1M0 G2 G12R Basal Classical Progenitor NO NA NO NA YES Pancreas|Other
TCGA-IB-7888-01A PDAC 66 NA no Female IIA T3N0M0 G2 Wild type Classical Classical Immunogenic NO NA NO NA Unknown NA
TCGA-IB-7889-01A PDAC 86 NA no Female IIB T3N1M0 G1 G12V Basal Exocrine ADEX NO NA NO NA YES Pancreas
TCGA-IB-7890-01A PDAC 73 NA yes Male IB T2N0M0 G3 Q61R Basal QM Squamous NO NA NO NA Unknown NA
TCGA-IB-7891-01A PDAC 50 29 yes Female IIB T3N1M0 G1 Wild type Classical Exocrine ADEX NO NA NO NA YES Other
TCGA-IB-7893-01A PDAC 65 NA yes Male IIA T3N0M0 G3 G12D Basal QM Squamous YES -38 NO NA YES Other
TCGA-IB-7897-01A PDAC 54 NA yes Female IIB T3N1M0 G2 G12D Basal QM Immunogenic NO NA NO NA YES Melanoma|Other
TCGA-IB-8126-01A PDAC 80 4 yes Female III T4N1M0 G1 G12D Classical Exocrine ADEX YES NA NO NA YES Other
TCGA-IB-8127-01A PDAC 59 40 NA Male IIB T3N1M0 G2 G12D Basal Exocrine Squamous NO NA NO NA NO NA
TCGA-IB-A5SO-01A PDAC 72 NA no Male IIB T3N1M0 G2 G12D Classical Classical Immunogenic NO NA NO NA NO NA
TCGA-IB-A5SP-01A PDAC 78 NA yes Male IIA T3N0M0 G2 G12D Classical Classical Progenitor NO NA NO NA YES Other
TCGA-IB-A5SQ-01A PDAC 57 NA yes Female IB T2N0M0 G2 Wild type Basal QM Immunogenic NO NA NO NA YES Other
TCGA-IB-A5SS-01A PDAC 64 NA no Female IIB T3N1M0 G3 G12D Basal QM Squamous YES -11 NO NA Unknown NA
TCGA-IB-A5ST-01A PDAC 65 NA no Female IIB T3N1M0 G2 G12D Classical QM Immunogenic NO NA NO NA YES Pancreas
TCGA-IB-A6UF-01A PDAC 63 NA yes Male IIB T3N1M0 G2 G12R Basal Exocrine Squamous YES -551 NO NA Unknown NA
TCGA-IB-A6UG-01A PDAC 65 NA yes Male IIB T3N1M0 G3 G12D Basal Exocrine ADEX NO NA NO NA Unknown NA
TCGA-IB-A7LX-01A PDAC 57 NA yes Male IIB T3N1MX G2 G12D Basal QM Squamous NO NA NO NA Unknown NA
TCGA-IB-A7M4-01A PDAC 82 52 yes Male IIB T3N1MX G3 G12D Basal Classical Squamous NO NA NO NA YES Other
TCGA-IB-AAUM-01A PDAC 77 NA yes Male IIB T2N1M0 G3 G12D Classical Exocrine ADEX YES NA NO NA Unknown NA
TCGA-IB-AAUN-01A PDAC 74 NA yes Female IB T2N0M0 G2 G12D Basal Exocrine ADEX NO NA NO NA YES Other
TCGA-IB-AAUO-01A PDAC 65 NA yes Female IIB T3N1M0 G3 G12D Basal QM Squamous NA NA NA NA NA NA
TCGA-IB-AAUP-01A PDAC 68 NA yes Male IIB T3N1M0 G2 G12D Classical QM Immunogenic YES NA NO NA YES Other
TCGA-IB-AAUQ-01A PDAC 50 23 yes Male IIB T3N1M0 G2 G12D Basal QM Squamous NO NA NO NA YES Other
TCGA-IB-AAUR-01A PDAC 67 NA yes Male IIB T3N1M0 G1 G12R Basal QM Immunogenic YES NA NO NA Unknown NA
TCGA-IB-AAUS-01A PDAC 84 65 yes Female IIB T3N1M0 G2 G12D Basal Exocrine Immunogenic YES -49 NO NA YES Other
TCGA-IB-AAUT-01A PDAC 65 15 yes Male IIB T2N1M0 G1 Wild type Classical Exocrine ADEX YES NA NO NA YES Breast|Other
TCGA-IB-AAUU-01A PDAC 36 NA yes Male IIB T3N1M0 G3 G12R Classical Classical Progenitor NO NA NO NA YES Other
TCGA-IB-AAUV-01A PDAC 49 NA yes Male IIB T3N1M0 G2 Wild type NA NA NA NO NA NO NA NO NA
TCGA-IB-AAUW-01A PDAC 64 NA yes Female IIB T3N1M0 G3 Wild type NA NA NA YES NA NO NA YES Other
TCGA-L1-A7W4-01A PDAC 49 NA yes Female IIB T3N1M0 G3 Wild type NA NA NA NO NA NO NA NO NA
TCGA-LB-A7SX-01A PDAC 75 NA yes Female IIB T3N1MX G2 Wild type Basal Classical Progenitor NO NA YES NA YES Breast
TCGA-LB-A8F3-01A PDAC 65 NA yes Female IIA T3N0MX G1 Wild type Classical Exocrine ADEX NO NA Unknown NA YES Other
TCGA-LB-A9Q5-01A PDAC 64 2 yes Female IIB T3N1MX G3 G12D Basal Exocrine ADEX NO NA NO NA YES Pancreas
TCGA-M8-A5N4-01A PDAC 48 NA yes Female IIA T3N0M0 G2 G12D Basal Classical Progenitor NO NA NO NA NA NA
TCGA-OE-A75W-01A PDAC 76 20 yes Male IIA T3N0M0 G1 G12D Classical Classical Progenitor YES NA YES -30 YES Other
TCGA-PZ-A5RE-01A PDAC 45 NA NA Female IIB T3N1MX G3 Q61H Classical Classical Progenitor NA NA NA NA NA NA
TCGA-Q3-A5QY-01A PDAC 58 NA no Male IIB T3N1MX G2 G12V Basal QM Immunogenic YES -139 NO NA NO NA
TCGA-Q3-AA2A-01A PDAC 65 NA yes Female IB T3N1MX G1 G12V Classical Classical Progenitor NO NA NA NA NA NA
TCGA-RB-A7B8-01A PDAC 81 NA yes Female IIB T3N1MX G2 G12R Classical Classical Progenitor NO NA NO NA YES Other
TCGA-RB-AA9M-01A PDAC 43 NA yes Male IIB T1N1MX G3 G12V Basal Classical Immunogenic NO NA NO NA YES Pancreas
TCGA-RL-AAAS-01A PDAC 61 NA yes Female IB T2N0M0 G2 Wild type NA NA NA YES NA NO 0 NO NA
TCGA-S4-A8RM-01A PDAC 67 25 yes Male IIB T3N1MX G3 G12V Classical Classical Progenitor YES NA NO NA YES Pancreas|Other
TCGA-S4-A8RO-01A PDAC 76 NA yes Female IIB T3N1MX G2 G12D Basal Classical Squamous NO NA NO NA NO NA
TCGA-S4-A8RP-01A PDAC 78 NA yes Female IIB T3N1MX G3 G12R Classical Exocrine Progenitor NO NA NO NA YES Other
TCGA-US-A774-01A PDAC 77 37 yes Female IIB T3N1MX G3 G12D Classical Exocrine ADEX NO NA NO NA YES Breast|Other
TCGA-US-A776-01A PDAC 61 NA yes Male IIA T3N0MX G2 Wild type Classical Classical Progenitor YES NA NO NA NO NA
TCGA-US-A779-01A PDAC 55 NA yes Female IIB T3N1bMX G1 G12D Classical Classical Progenitor NO NA NO NA NO NA
TCGA-US-A77E-01A PDAC 73 NA yes Male IIB T3N1MX G3 Wild type Classical Classical Progenitor NO NA NO NA YES Other
TCGA-US-A77G-01A PDAC 64 NA yes Male IIB T3N1MX G2 G12R Classical Exocrine Progenitor NO NA NO NA Unknown NA
TCGA-US-A77J-01A PDAC 82 NA yes Female IIB T3N1bMX G2 Wild type NA NA NA NO NA NO NA YES Pancreas
TCGA-XD-AAUG-01A PDAC 67 NA yes Female IV T3N1M1 G2 G12V Classical Exocrine Immunogenic Unknown NA NA NA YES Breast|Other
TCGA-XD-AAUH-01A PDAC 57 NA yes Female IIB T3N1M0 G2 UNKNOWN Basal QM Immunogenic NO NA NO NA YES Other
TCGA-XD-AAUI-01A PDAC 51 NA yes Female IIB T3N1MX G2 G12V Basal Exocrine Immunogenic YES NA NA NA NO NA
TCGA-XD-AAUL-01A PDAC 56 NA yes Male IIA T3N0MX G2 G12R Basal Classical Squamous NO NA YES -418 NO NA
TCGA-XN-A8T3-01A PDAC 68 NA no Male IB T2N0M0 G2 G12D Basal Exocrine ADEX NO NA NO NA NA NA
TCGA-XN-A8T5-01A PDAC 54 NA no Female IB T2N0M0 G2 G12R Basal QM Immunogenic YES NA NO NA NA NA
TCGA-YB-A89D-01A PDAC 60 NA no Male IIB T3N1MX G2 G12D,G12R Classical Classical Progenitor YES NA NO NA YES Other
TCGA-YB-A89D-11A Normal 60 NA no Male IIB T3N1MX G2 NA NA NA NA YES NA NO NA YES Other
TCGA-YH-A8SY-01A PDAC 74 NA yes Female NA T3N1MX G2 G12V Basal QM Squamous NO NA NO NA NO NA
TCGA-YY-A8LH-01A PDAC 61 NA yes Female IIB T3N1MX G3 G12V Classical Classical Progenitor NO NA NO NA YES Breast|Other
TCGA-Z5-AAPL-01A PDAC 74 NA NA Female IIA T3N0M0 G1 G12V Classical QM Immunogenic NA NA NA NA NA NA
The Cancer Genome Atlas Patient Statistics
Definition
Gender
Age
Grade

The Cancer Genome Atlas Molecular Statistics
Moffitt Subtype
KRAS Variant
Collisson Subtype
Bailey Subtype
Loading...
Loading...
CGI Biomarker CGI Bioactivity
Gene Protein Alteration Alteration Match Drug Effect Tumour Evidence
KRAS G12R Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12R Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12R Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12R Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12R Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12R Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12R Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12R Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12R Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12R Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12R Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12R Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12R Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12R Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12R Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12R Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12R Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12R Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12R Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12R Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12R Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12R Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12R Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12R Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12R Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12R Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12R Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12R Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12R Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12R Complete Match FAS inhibitor Responsive L Case report
KRAS G12R Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12R Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12R Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12R Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12R Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12R Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12R Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12R Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12R Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12R Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 Y126N Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Y126N Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Y126N Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Y126N Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Y126N Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Y126N Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y126N Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y126N Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y126N Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Y126N Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Y126N Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Y126N Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y126N Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Y126N Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y126N Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
KRAS G12V Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12V Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12V Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12V Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12V Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12V Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12V Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12V Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12V Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12V Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12V Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12V Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12V Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12V Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12V Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12V Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12V Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12V Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12V Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12V Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12V Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12V Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12V Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12V Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12V Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12V Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12V Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12V Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12V Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12V Complete Match FAS inhibitor Responsive L Case report
KRAS G12V Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12V Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12V Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12V Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12V Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12V Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12V Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12V Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12V Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12V Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 R273H Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R273H Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R273H Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R273H Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R273H Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R273H Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R273H Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R273H Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R273H Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R273H Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R273H Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R273H Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R273H Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R273H Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R273H Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S166* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 S166* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 S166* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 S166* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 S166* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 S166* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S166* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S166* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S166* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 S166* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 S166* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 S166* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S166* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 S166* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S166* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ALK R1212H Different Alteration ALK inhibitor;SRC inhibitor Responsive LUAD Pre-clinical
ALK R1212H Different Alteration Crizotinib (ALK inhibitor) Responsive GB, LY Early trials
ALK R1212H Different Alteration Lorlatinib (ALK&ROS1 inhibitor) Responsive NSCLC Early trials
ALK R1212H Different Alteration Crizotinib (ALK inhibitor) Responsive THCA, IM Case report
ALK R1212H Different Alteration HSP90 inhibitor Responsive LUAD Early trials
ALK R1212H Different Alteration Ceritinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK R1212H Different Alteration Ceritinib (ALK inhibitor) Responsive IM, COREAD Case report
ALK R1212H Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK R1212H Different Alteration Brigatinib (Pan-TK inhibitor) Responsive NSCLC FDA guidelines
ALK R1212H Different Alteration Entrictinib (Pan-TK inhibitor) Responsive COREAD Case report
ALK R1212H Different Alteration Alectinib (ALK inhibitor) Responsive LUAD FDA guidelines
ALK R1212H Different Alteration HSP90 inhibitor (HSP90 inhibitor) Responsive LUAD Early trials
ALK R1212H Different Alteration ALK inhibitor;IGF1R inhibitor Responsive LUAD Pre-clinical
ALK R1212H Different Alteration ALK inhibitor;MEK inhibitor Responsive LUAD Pre-clinical
ALK R1212H Different Alteration novel ALK inhibitor Responsive LUAD Early trials
ALK R1212H Different Alteration Ceritinib (ALK inhibitor) Responsive HEMATO Early trials
ALK R1212H Different Alteration ALK inhibitor Responsive COREAD Case report
ALK R1212H Different Alteration Alectinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ALK R1212H Different Alteration MEK inhibitor (ALK inhibitor;MEK inhibitor) Responsive LUAD Pre-clinical
TP53 Q104* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Q104* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Q104* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Q104* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Q104* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Q104* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Q104* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Q104* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Q104* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Q104* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Q104* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Q104* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Q104* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Q104* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Q104* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ARID1A E1542* Complete Match EZH2 inhibitor Responsive OV Pre-clinical
ARID1A E1542* Complete Match PD1 inhibitor Responsive OV Pre-clinical
ARID1A E1542* Complete Match PARP inhibitor Responsive CANCER Pre-clinical
ARID1A E1542* Complete Match ATR inhibitor Responsive CANCER Pre-clinical
NF1 Q1070* Different Mutation Vemurafenib (BRAF inhibitor) Resistant CM Pre-clinical
NF1 Q1070* Different Mutation Everolimus (MTOR inhibitor) Responsive HNC Case report
NF1 Q1070* Complete Match Sirolimus (MTOR inhibitor) Responsive PLEN Early trials
NF1 Q1070* Complete Match Vinblastine (Chemotherapy) Responsive G Early trials
NF1 Q1070* Complete Match KIT inhibitor;MTOR inhibitor Responsive MPN Pre-clinical
NF1 Q1070* Complete Match Tamoxifen (Hormonal therapy) Responsive MPN Pre-clinical
NF1 Q1070* Complete Match Bevacizumab (VEGFR mAb inhibitor) Responsive G Case report
NF1 Q1070* Complete Match Retinoic Acid Resistant NB Pre-clinical
NF1 Q1070* Complete Match Everolimus (MTOR inhibitor) Responsive NF Late trials
NF1 Q1070* Complete Match Trametinib (MEK inhibitor) Responsive G Case report
NF1 Q1070* Complete Match Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) Responsive MPN Pre-clinical
NF1 Q1070* Complete Match Nilotinib (BCR-ABL inhibitor) Responsive MPN, PLEN Pre-clinical
NF1 Q1070* Complete Match MEK inhibitor Responsive MPN Pre-clinical
NF1 Q1070* Complete Match Everolimus (MTOR inhibitor) Responsive HNC, SG Case report
NF1 Q1070* Complete Match Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) No Responsive MPN Early trials
NF1 Q1070* Complete Match PLX3397 (Pan-TK inhibitor) Responsive PLEN Pre-clinical
NF1 Q1070* Complete Match MEK inhibitor Responsive LK, G Pre-clinical
NF1 Q1070* Complete Match Pan-RAF inhibitor;MEK inhibitor Responsive CM Pre-clinical
NF1 Q1070* Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive PLEN Early trials
NF1 Q1070* Complete Match AURK inhibitor Responsive MPN Pre-clinical
NF1 Q1070* Complete Match MTOR inhibitor Responsive LK, G, MPN Pre-clinical
NF1 Q1070* Complete Match Dasatinib (BCR-ABL inhibitor) Resistant L Pre-clinical
NF1 Q1070* Complete Match Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) Responsive HC Case report
NF1 Q1070* Complete Match Everolimus (MTOR inhibitor) No Responsive MPN Early trials
NF1 Q1070* Complete Match Cediranib (ALK inhibitor) No Responsive PLEN Early trials
NF1 Q1070* Complete Match PD1 Ab inhibitor Responsive CM Early trials
NF1 Q1070* Complete Match Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) Responsive G Case report
NF1 Q1070* Complete Match Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) Responsive G Case report
NF1 Q1070* Complete Match Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) No Responsive G Case report
NF1 Q1070* Complete Match BRD4 inhibitor Responsive MPN Pre-clinical
NF1 Q1070* Complete Match Tipifarnib (Farnesyltransferase inhibitor) No Responsive PLEN Early trials
NF1 Q1070* Complete Match Selumetinib (MEK inhibitor) Responsive PLEN Early trials
NF1 Q1070* Complete Match MTOR inhibitor;HSP90 inhibitor Responsive MPN Pre-clinical
NF1 Q1070* Complete Match Trametinib (MEK inhibitor) Responsive CM Pre-clinical
NF1 Q1070* Complete Match Erlotinib (EGFR inhibitor) Resistant L Pre-clinical
NF1 Q1070* Complete Match Trametinib (MEK inhibitor) No Responsive OS Case report
NF1 Q1070* Different Alteration MTOR inhibitor Responsive MPN, G, LK Pre-clinical
NF1 Q1070* Different Alteration PLX3397 (Pan-TK inhibitor) Responsive PLEN Pre-clinical
NF1 Q1070* Different Alteration Erlotinib (EGFR inhibitor) Resistant L Pre-clinical
NF1 Q1070* Different Alteration Trametinib (MEK inhibitor) Responsive G Case report
NF1 Q1070* Different Alteration BRD4 inhibitor Responsive MPN Pre-clinical
NF1 Q1070* Different Alteration Trametinib (MEK inhibitor) No Responsive OS Case report
NF1 Q1070* Different Alteration Cediranib (ALK inhibitor) No Responsive PLEN Early trials
NF1 Q1070* Different Alteration Bevacizumab (VEGFR mAb inhibitor) Responsive G Case report
NF1 Q1070* Different Alteration MEK inhibitor Responsive G, LK Pre-clinical
NF1 Q1070* Different Alteration Vinblastine (Chemotherapy) Responsive G Early trials
NF1 Q1070* Different Alteration Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) Responsive MPN Pre-clinical
NF1 Q1070* Different Alteration Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) No Responsive MPN Early trials
NF1 Q1070* Different Alteration Dasatinib (BCR-ABL inhibitor) Resistant L Pre-clinical
NF1 Q1070* Different Alteration MTOR inhibitor;HSP90 inhibitor Responsive MPN Pre-clinical
NF1 Q1070* Different Alteration Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) Responsive G Case report
NF1 Q1070* Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive PLEN Early trials
NF1 Q1070* Different Alteration Tamoxifen (Hormonal therapy) Responsive MPN Pre-clinical
NF1 Q1070* Different Alteration Everolimus (MTOR inhibitor) Responsive SG, HNC Case report
NF1 Q1070* Different Alteration Pan-RAF inhibitor;MEK inhibitor Responsive CM Pre-clinical
NF1 Q1070* Different Alteration Tipifarnib (Farnesyltransferase inhibitor) No Responsive PLEN Early trials
NF1 Q1070* Different Alteration Selumetinib (MEK inhibitor) Responsive PLEN Early trials
NF1 Q1070* Different Alteration Retinoic Acid Resistant NB Pre-clinical
NF1 Q1070* Different Alteration Everolimus (MTOR inhibitor) No Responsive MPN Early trials
NF1 Q1070* Different Alteration Sirolimus (MTOR inhibitor) Responsive PLEN Early trials
NF1 Q1070* Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive PLEN, MPN Pre-clinical
NF1 Q1070* Different Alteration Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) Responsive G Case report
NF1 Q1070* Different Alteration Trametinib (MEK inhibitor) Responsive CM Pre-clinical
NF1 Q1070* Different Alteration AURK inhibitor Responsive MPN Pre-clinical
NF1 Q1070* Different Alteration Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) No Responsive G Case report
NF1 Q1070* Different Alteration PD1 Ab inhibitor Responsive CM Early trials
NF1 Q1070* Different Alteration MEK inhibitor Responsive MPN Pre-clinical
NF1 Q1070* Different Alteration KIT inhibitor;MTOR inhibitor Responsive MPN Pre-clinical
AKT3 V190A Different Alteration ATP competitive AKT inhibitor Responsive BRCA Pre-clinical
RNF43 Q22* Complete Match Porcupine inhibitor Responsive COREAD Case report
TP53 C242* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 C242* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 C242* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 C242* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 C242* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 C242* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C242* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C242* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C242* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 C242* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 C242* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 C242* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C242* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 C242* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C242* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
KRAS G12D Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12D Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12D Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12D Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12D Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12D Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12D Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12D Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12D Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12D Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12D Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12D Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12D Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12D Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12D Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12D Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12D Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12D Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12D Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12D Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12D Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12D Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12D Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12D Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12D Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12D Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12D Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12D Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12D Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12D Complete Match FAS inhibitor Responsive L Case report
KRAS G12D Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12D Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12D Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12D Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12D Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12D Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12D Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12D Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12D Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12D Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
CDKN2A R80* Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A R80* Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A R80* Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A R80* Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A R80* Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A R80* Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A R80* Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A R80* Different Alteration CDK4/6 inhibitor Responsive CM Case report
KRAS G12S Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12S Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12S Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12S Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12S Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12S Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12S Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12S Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12S Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12S Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12S Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12S Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12S Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12S Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12S Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12S Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12S Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12S Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12S Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12S Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12S Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12S Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12S Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12S Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12S Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12S Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12S Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12S Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12S Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12S Complete Match FAS inhibitor Responsive L Case report
KRAS G12S Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12S Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12S Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12S Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12S Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12S Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12S Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12S Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12S Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12S Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 V272A Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 V272A Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 V272A Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 V272A Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 V272A Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 V272A Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V272A Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V272A Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V272A Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 V272A Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 V272A Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 V272A Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V272A Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 V272A Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V272A Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
BRAF R462T Different Mutation Dasatinib (BCR-ABL inhibitor) Responsive LUAD Pre-clinical
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Responsive HISEC, HISLC, NSCLC NCCN guidelines
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Responsive CM NCCN guidelines
BRAF R462T Different Mutation Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) Responsive CM FDA guidelines
BRAF R462T Different Mutation Trametinib (MEK inhibitor) Responsive CM FDA guidelines
BRAF R462T Different Mutation Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) Responsive CM FDA guidelines
BRAF R462T Different Mutation Pan-RAF inhibitor Responsive CANCER Pre-clinical
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Resistant CANCER Pre-clinical
BRAF R462T Different Mutation ERK inhibitor Responsive HNSC, BT Case report
BRAF R462T Different Mutation EGFR TK inhibitor Resistant LUAD Case report
BRAF R462T Different Mutation MEK inhibitor Responsive CM Case report
BRAF R462T Different Mutation Dabrafenib (BRAF inhibitor) Responsive CM Early trials
BRAF R462T Different Mutation BRAF inhibitor Responsive CM Case report
BRAF R462T Different Mutation Sorafenib (Pan-TK inhibitor) Responsive CM Pre-clinical
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) No Responsive COREAD Early trials
BRAF R462T Different Mutation MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) Responsive COREAD Early trials
BRAF R462T Different Mutation Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) Responsive COREAD NCCN guidelines
BRAF R462T Different Mutation Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) Responsive COREAD Early trials
BRAF R462T Different Mutation BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor Responsive COREAD Early trials
BRAF R462T Different Mutation BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor Responsive COREAD Early trials
BRAF R462T Different Mutation Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) Responsive COREAD Early trials
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Responsive MA Early trials
BRAF R462T Different Mutation BRAF inhibitor;MEK inhibitor Responsive TH Early trials
BRAF R462T Different Mutation BRAF inhibitor;HSP90 inhibitor Responsive CM Pre-clinical
BRAF R462T Different Mutation Panitumumab (EGFR mAb inhibitor) Resistant COREAD Late trials
BRAF R462T Different Mutation Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) Responsive COREAD Early trials
BRAF R462T Different Mutation Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) Responsive LUAD FDA guidelines
BRAF R462T Different Mutation Dabrafenib (BRAF inhibitor) Responsive NSCLC NCCN guidelines
BRAF R462T Different Mutation MEK inhibitor Responsive TH Early trials
BRAF R462T Different Mutation BRAF inhibitor;PI3K pathway inhibitor Responsive CM Pre-clinical
BRAF R462T Different Mutation Dabrafenib (BRAF inhibitor) Responsive LUAD, TH Early trials
BRAF R462T Different Mutation MEK inhibitor Responsive OV Pre-clinical
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Responsive CM FDA guidelines
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Responsive HCL, LUAD, MYMA Case report
BRAF R462T Different Mutation Pan-RAF inhibitor Responsive CM Early trials
BRAF R462T Different Mutation Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
BRAF R462T Different Mutation BRAF inhibitor Responsive G Pre-clinical
BRAF R462T Different Mutation BRAF inhibitor;CDK2/4 inhibitor Responsive CM Pre-clinical
BRAF R462T Different Mutation PLX4720 (BRAF inhibitor) Responsive MA Pre-clinical
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Responsive THCA Early trials
BRAF R462T Different Mutation Selumetinib (MEK inhibitor) Responsive PG Early trials
BRAF R462T Different Mutation ERK inhibitor Responsive LUAD Early trials
BRAF R462T Different Mutation ERK inhibitor Responsive CM Pre-clinical
BRAF R462T Different Mutation Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) Responsive NEU Case report
BRAF R462T Different Mutation BRAF inhibitor Responsive OV Case report
BRAF R462T Different Mutation Dabrafenib (BRAF inhibitor) Responsive GIST Case report
BRAF R462T Different Mutation Dabrafenib (BRAF inhibitor) Responsive CM FDA guidelines
BRAF R462T Different Mutation Dasatinib (BCR-ABL inhibitor) Responsive LUAD Case report
BRAF R462T Different Alteration Sorafenib (Pan-TK inhibitor) Responsive CM, LUAD, PRAD Pre-clinical
BRAF R462T Different Alteration MEK inhibitor Responsive LUAD, CM, PRAD Pre-clinical
BRAF R462T Different Alteration Selumetinib (MEK inhibitor) Responsive OV Case report
BRAF R462T Different Alteration BRAF inhibitor;MEK inhibitor Responsive LUAD Case report
TP53 G266V Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G266V Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G266V Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G266V Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G266V Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G266V Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G266V Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G266V Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G266V Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G266V Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G266V Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G266V Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G266V Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G266V Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G266V Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G245D Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G245D Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G245D Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G245D Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G245D Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G245D Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G245D Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G245D Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G245D Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G245D Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G245D Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G245D Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G245D Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G245D Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G245D Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 H214R Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 H214R Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 H214R Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 H214R Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 H214R Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 H214R Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 H214R Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 H214R Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 H214R Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 H214R Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 H214R Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 H214R Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 H214R Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 H214R Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 H214R Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R175H Complete Match HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R175H Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R175H Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R175H Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R175H Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R175H Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R175H Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R175H Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R175H Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R175H Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R175H Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R175H Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R175H Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R175H Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R175H Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
PIK3CA P539R Different Mutation BRAF inhibitor Resistant CM Case report
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive BLCA, HNC Case report
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive HNSC Case report
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive G, THCA Pre-clinical
PIK3CA P539R Complete Match Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) Responsive BRCA Late trials
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive COREAD Pre-clinical
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive ED, OV, CESC Early trials
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive BRCA Late trials
PIK3CA P539R Complete Match PIK3CA inhibitor Responsive BRCA Early trials
PIK3CA P539R Complete Match PIK3CA inhibitor Responsive ST Case report
PIK3CA P539R Complete Match AKT inhibitor Responsive BRCA Early trials
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive;Responsive L Pre-clinical;Case report
PIK3CA P539R Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
PIK3CA P539R Different Alteration PI3K pathway inhibitor Resistant BRCA Pre-clinical
CDKN2A H83Y Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A H83Y Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A H83Y Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A H83Y Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A H83Y Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A H83Y Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A H83Y Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A H83Y Different Alteration CDK4/6 inhibitor Responsive CM Case report
TP53 Q38* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Q38* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Q38* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Q38* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Q38* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Q38* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Q38* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Q38* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Q38* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Q38* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Q38* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Q38* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Q38* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Q38* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Q38* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R283P Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R283P Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R283P Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R283P Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R283P Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R283P Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R283P Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R283P Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R283P Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R283P Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R283P Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R283P Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R283P Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R283P Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R283P Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NRG1 intron_variant Different Alteration Lapatinib (ERBB2 inhibitor) Responsive LUAD Pre-clinical
NRG1 intron_variant Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Case report
TP53 G266E Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G266E Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G266E Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G266E Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G266E Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G266E Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G266E Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G266E Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G266E Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G266E Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G266E Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G266E Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G266E Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G266E Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G266E Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
KRAS Q61R Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS Q61R Different Mutation Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS Q61R Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS Q61R Different Mutation MEK inhibitor Responsive ALL Pre-clinical
KRAS Q61R Different Mutation Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS Q61R Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS Q61R Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS Q61R Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS Q61R Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS Q61R Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS Q61R Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS Q61R Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS Q61R Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS Q61R Complete Match BET inhibitor Responsive L Pre-clinical
KRAS Q61R Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS Q61R Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS Q61R Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS Q61R Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS Q61R Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS Q61R Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS Q61R Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS Q61R Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS Q61R Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS Q61R Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS Q61R Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS Q61R Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS Q61R Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS Q61R Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS Q61R Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS Q61R Complete Match FAS inhibitor Responsive L Case report
KRAS Q61R Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS Q61R Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS Q61R Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS Q61R Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS Q61R Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS Q61R Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS Q61R Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS Q61R Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS Q61R Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS Q61R Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 splice_acceptor_variant Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 splice_acceptor_variant Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 splice_acceptor_variant Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 splice_acceptor_variant Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 splice_acceptor_variant Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 splice_acceptor_variant Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 splice_acceptor_variant Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 splice_acceptor_variant Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 splice_acceptor_variant Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 splice_acceptor_variant Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 splice_acceptor_variant Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 splice_acceptor_variant Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 splice_acceptor_variant Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 splice_acceptor_variant Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 splice_acceptor_variant Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G245S Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G245S Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G245S Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G245S Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G245S Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G245S Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G245S Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G245S Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G245S Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G245S Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G245S Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G245S Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G245S Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G245S Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G245S Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y220C Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Y220C Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Y220C Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Y220C Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Y220C Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Y220C Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y220C Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y220C Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y220C Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Y220C Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Y220C Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Y220C Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y220C Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Y220C Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y220C Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V143E Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 V143E Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 V143E Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 V143E Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 V143E Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 V143E Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V143E Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V143E Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V143E Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 V143E Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 V143E Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 V143E Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V143E Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 V143E Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V143E Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
CDKN2A E120* Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A E120* Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A E120* Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A E120* Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A E120* Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A E120* Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A E120* Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A E120* Different Alteration CDK4/6 inhibitor Responsive CM Case report
NTRK1 G357S Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Case report
NTRK1 G357S Different Alteration Pan-TKR inhibitor Responsive CANCER Early trials
NTRK1 G357S Different Alteration Pan-TK inhibitor Responsive LUAD Pre-clinical
NTRK1 G357S Different Alteration Pan-TK inhibitor Responsive COREAD Case report
TP53 S241Y Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 S241Y Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 S241Y Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 S241Y Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 S241Y Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 S241Y Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S241Y Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S241Y Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S241Y Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 S241Y Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 S241Y Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 S241Y Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S241Y Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 S241Y Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S241Y Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
KMT2A L2896I Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A L2896I Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A L2896I Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A L2896I Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A L2896I Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A L2896I Different Alteration DOT1L inhibitor Responsive AML Early trials
NOTCH1 V453I Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 V453I Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
TP53 splice_donor_variant Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 splice_donor_variant Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 splice_donor_variant Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 splice_donor_variant Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 splice_donor_variant Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 splice_donor_variant Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 splice_donor_variant Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 splice_donor_variant Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 splice_donor_variant Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 splice_donor_variant Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 splice_donor_variant Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 splice_donor_variant Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 splice_donor_variant Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 splice_donor_variant Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 splice_donor_variant Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
CTNNB1 S45P Different Mutation Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) Responsive ED Early trials
CTNNB1 S45P Complete Match Tankyrase inhibitor Resistant COREAD Pre-clinical
TP53 E294* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 E294* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 E294* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 E294* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 E294* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 E294* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 E294* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E294* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E294* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 E294* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 E294* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 E294* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E294* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 E294* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E294* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
RNF43 R145* Complete Match Porcupine inhibitor Responsive COREAD Case report
TP53 V197M Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 V197M Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 V197M Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 V197M Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 V197M Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 V197M Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V197M Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V197M Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V197M Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 V197M Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 V197M Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 V197M Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V197M Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 V197M Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V197M Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ARID1A R1276* Complete Match EZH2 inhibitor Responsive OV Pre-clinical
ARID1A R1276* Complete Match PD1 inhibitor Responsive OV Pre-clinical
ARID1A R1276* Complete Match PARP inhibitor Responsive CANCER Pre-clinical
ARID1A R1276* Complete Match ATR inhibitor Responsive CANCER Pre-clinical
ARID1A splice_donor_variant Complete Match EZH2 inhibitor Responsive OV Pre-clinical
ARID1A splice_donor_variant Complete Match PD1 inhibitor Responsive OV Pre-clinical
ARID1A splice_donor_variant Complete Match PARP inhibitor Responsive CANCER Pre-clinical
ARID1A splice_donor_variant Complete Match ATR inhibitor Responsive CANCER Pre-clinical
ZNRF3 Q411* Complete Match Porcupine inhibitor Responsive COREAD Pre-clinical
TP53 R273C Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R273C Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R273C Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R273C Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R273C Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R273C Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R273C Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R273C Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R273C Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R273C Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R273C Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R273C Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R273C Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R273C Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R273C Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NTRK3 M567T Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 M567T Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 M567T Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
KRAS Q61H Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS Q61H Different Mutation Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS Q61H Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS Q61H Different Mutation MEK inhibitor Responsive ALL Pre-clinical
KRAS Q61H Different Mutation Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS Q61H Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS Q61H Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS Q61H Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS Q61H Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS Q61H Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS Q61H Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS Q61H Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS Q61H Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS Q61H Complete Match BET inhibitor Responsive L Pre-clinical
KRAS Q61H Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS Q61H Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS Q61H Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS Q61H Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS Q61H Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS Q61H Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS Q61H Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS Q61H Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS Q61H Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS Q61H Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS Q61H Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS Q61H Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS Q61H Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS Q61H Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS Q61H Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS Q61H Complete Match FAS inhibitor Responsive L Case report
KRAS Q61H Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS Q61H Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS Q61H Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS Q61H Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS Q61H Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS Q61H Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS Q61H Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS Q61H Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS Q61H Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS Q61H Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
KRAS G13C Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G13C Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G13C Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G13C Different Mutation MEK inhibitor Responsive ALL Pre-clinical
KRAS G13C Different Mutation Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G13C Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G13C Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G13C Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G13C Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G13C Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G13C Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G13C Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G13C Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G13C Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G13C Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G13C Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G13C Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G13C Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G13C Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G13C Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G13C Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G13C Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G13C Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G13C Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G13C Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G13C Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G13C Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G13C Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G13C Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G13C Complete Match FAS inhibitor Responsive L Case report
KRAS G13C Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G13C Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G13C Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G13C Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G13C Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G13C Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G13C Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G13C Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G13C Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G13C Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 R248L Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R248L Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R248L Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R248L Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R248L Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R248L Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R248L Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248L Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248L Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R248L Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R248L Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R248L Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248L Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R248L Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248L Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
KRAS G12A Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12A Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12A Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12A Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12A Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12A Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12A Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12A Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12A Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12A Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12A Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12A Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12A Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12A Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12A Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12A Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12A Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12A Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12A Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12A Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12A Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12A Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12A Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12A Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12A Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12A Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12A Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12A Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12A Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12A Complete Match FAS inhibitor Responsive L Case report
KRAS G12A Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12A Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12A Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12A Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12A Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12A Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12A Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12A Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12A Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12A Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
NTRK1 I491I Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Case report
NTRK1 I491I Different Alteration Pan-TKR inhibitor Responsive CANCER Early trials
NTRK1 I491I Different Alteration Pan-TK inhibitor Responsive LUAD Pre-clinical
NTRK1 I491I Different Alteration Pan-TK inhibitor Responsive COREAD Case report
GNAS R201C Complete Match JAK inhibitor Responsive CANCER Pre-clinical
ESR1 S576S Different Alteration ESR1 inhibitor Resistant BRCA Pre-clinical
TP53 H179Y Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 H179Y Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 H179Y Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 H179Y Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 H179Y Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 H179Y Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 H179Y Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 H179Y Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 H179Y Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 H179Y Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 H179Y Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 H179Y Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 H179Y Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 H179Y Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 H179Y Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R213* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R213* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R213* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R213* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R213* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R213* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R213* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R213* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R213* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R213* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R213* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R213* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R213* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R213* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R213* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y205S Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Y205S Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Y205S Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Y205S Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Y205S Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Y205S Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y205S Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y205S Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y205S Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Y205S Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Y205S Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Y205S Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y205S Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Y205S Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y205S Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P278S Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 P278S Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 P278S Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 P278S Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 P278S Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 P278S Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P278S Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P278S Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P278S Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 P278S Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 P278S Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 P278S Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P278S Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 P278S Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P278S Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
JAK2 K385K Different Alteration Ruxolitinib (JAK inhibitor) Responsive ALL Pre-clinical
TP53 R248Q Complete Match HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R248Q Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R248Q Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R248Q Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R248Q Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R248Q Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R248Q Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248Q Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248Q Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R248Q Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R248Q Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R248Q Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248Q Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R248Q Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248Q Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
PIK3CA G118D Different Mutation BRAF inhibitor Resistant CM Case report
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive BLCA, HNC Case report
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive HNSC Case report
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive G, THCA Pre-clinical
PIK3CA G118D Complete Match Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) Responsive BRCA Late trials
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive COREAD Pre-clinical
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive ED, OV, CESC Early trials
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive BRCA Late trials
PIK3CA G118D Complete Match PIK3CA inhibitor Responsive BRCA Early trials
PIK3CA G118D Complete Match PIK3CA inhibitor Responsive ST Case report
PIK3CA G118D Complete Match AKT inhibitor Responsive BRCA Early trials
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive;Responsive L Pre-clinical;Case report
PIK3CA G118D Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
PIK3CA G118D Different Alteration PI3K pathway inhibitor Resistant BRCA Pre-clinical
TP53 V173L Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 V173L Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 V173L Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 V173L Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 V173L Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 V173L Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V173L Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V173L Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V173L Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 V173L Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 V173L Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 V173L Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V173L Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 V173L Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V173L Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ATR E1765* Complete Match Temozolomide (Chemotherapy) Responsive G Pre-clinical
ATR E1765* Complete Match Olaparib (PARP inhibitor) Responsive CANCER, OV Pre-clinical
ATR E1765* Different Alteration Olaparib (PARP inhibitor) Responsive OV, CANCER Pre-clinical
TP53 P152L Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 P152L Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 P152L Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 P152L Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 P152L Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 P152L Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P152L Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P152L Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P152L Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 P152L Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 P152L Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 P152L Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P152L Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 P152L Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P152L Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
LRP1B R3064* Complete Match Liposomal Doxorubicin (Chemotherapy) Resistant OV Early trials
LRP1B R3064* Different Alteration Liposomal Doxorubicin (Chemotherapy) Resistant OV Early trials
BAP1 splice_acceptor_variant Complete Match EZH2 inhibitor Responsive MESO Pre-clinical
BAP1 splice_acceptor_variant Complete Match PARP inhibitor Responsive R, CANCER Pre-clinical
BAP1 splice_acceptor_variant Complete Match HDAC inhibitor Responsive CM Pre-clinical
BAP1 splice_acceptor_variant Different Alteration PARP inhibitor Responsive CANCER, R Pre-clinical
BAP1 splice_acceptor_variant Different Alteration EZH2 inhibitor Responsive MESO Pre-clinical
BAP1 splice_acceptor_variant Different Alteration HDAC inhibitor Responsive CM Pre-clinical
TP53 C238Y Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 C238Y Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 C238Y Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 C238Y Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 C238Y Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 C238Y Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C238Y Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C238Y Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C238Y Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 C238Y Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 C238Y Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 C238Y Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C238Y Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 C238Y Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C238Y Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
CDKN2A W15* Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A W15* Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A W15* Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A W15* Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A W15* Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A W15* Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A W15* Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A W15* Different Alteration CDK4/6 inhibitor Responsive CM Case report
TP53 R282G Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R282G Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R282G Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R282G Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R282G Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R282G Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R282G Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R282G Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R282G Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R282G Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R282G Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R282G Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R282G Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R282G Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R282G Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R248W Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R248W Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R248W Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R248W Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R248W Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R248W Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R248W Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248W Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248W Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R248W Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R248W Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R248W Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248W Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R248W Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248W Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y205F Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Y205F Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Y205F Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Y205F Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Y205F Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Y205F Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y205F Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y205F Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y205F Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Y205F Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Y205F Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Y205F Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y205F Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Y205F Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y205F Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
BCR R447H Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
BCR R447H Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
BCR R447H Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR R447H Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR R447H Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
BCR R447H Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
RNF43 splice_donor_variant Complete Match Porcupine inhibitor Responsive COREAD Case report
TP53 N131I Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 N131I Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 N131I Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 N131I Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 N131I Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 N131I Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 N131I Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 N131I Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 N131I Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 N131I Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 N131I Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 N131I Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 N131I Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 N131I Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 N131I Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
APC R499* Complete Match Tankyrase inhibitor Responsive COREAD Pre-clinical
TP53 P151R Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 P151R Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 P151R Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 P151R Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 P151R Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 P151R Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P151R Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P151R Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P151R Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 P151R Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 P151R Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 P151R Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P151R Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 P151R Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P151R Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 D259V Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 D259V Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 D259V Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 D259V Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 D259V Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 D259V Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 D259V Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 D259V Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 D259V Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 D259V Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 D259V Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 D259V Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 D259V Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 D259V Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 D259V Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ATM splice_acceptor_variant Different Mutation AZD6738 (ATR inhibitor) Responsive BCL Early trials
ATM splice_acceptor_variant Complete Match Cisplatin (Chemotherapy) Responsive BLCA Early trials
ATM splice_acceptor_variant Complete Match Olaparib (PARP inhibitor) Responsive ST, PRAD Early trials
ATM splice_acceptor_variant Complete Match PARP inhibitor Responsive ST Early trials
ATM splice_acceptor_variant Complete Match ATR inhibitor Responsive COREAD Case report
ATM splice_acceptor_variant Complete Match DNA-PKc inhibitor Responsive LY Pre-clinical
ATM splice_acceptor_variant Complete Match Temozolomide (Chemotherapy) Responsive G Pre-clinical
ATM splice_acceptor_variant Complete Match PD1/PDL1 inhibitor Responsive UTH Early trials
ATM splice_acceptor_variant Different Alteration PD1/PDL1 inhibitor Responsive UTH Early trials
ATM splice_acceptor_variant Different Alteration DNA-PKc inhibitor Responsive LY Pre-clinical
ATM splice_acceptor_variant Different Alteration PARP inhibitor Responsive ST Early trials
ATM splice_acceptor_variant Different Alteration ATR inhibitor Responsive COREAD Case report
ATM splice_acceptor_variant Different Alteration Cisplatin (Chemotherapy) Responsive BLCA Early trials
KMT2A P3059L Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A P3059L Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A P3059L Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A P3059L Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A P3059L Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A P3059L Different Alteration DOT1L inhibitor Responsive AML Early trials
BRD4 L894F Different Alteration BET inhibitor Responsive NMC Case report
TP53 R196* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R196* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R196* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R196* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R196* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R196* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R196* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R196* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R196* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R196* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R196* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R196* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R196* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R196* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R196* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C135* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 C135* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 C135* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 C135* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 C135* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 C135* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C135* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C135* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C135* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 C135* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 C135* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 C135* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C135* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 C135* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C135* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ERBB4 C213C Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
ARID1A Q1947* Complete Match EZH2 inhibitor Responsive OV Pre-clinical
ARID1A Q1947* Complete Match PD1 inhibitor Responsive OV Pre-clinical
ARID1A Q1947* Complete Match PARP inhibitor Responsive CANCER Pre-clinical
ARID1A Q1947* Complete Match ATR inhibitor Responsive CANCER Pre-clinical
ERBB4 V299E Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
TP53 H179R Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 H179R Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 H179R Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 H179R Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 H179R Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 H179R Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 H179R Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 H179R Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 H179R Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 H179R Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 H179R Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 H179R Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 H179R Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 H179R Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 H179R Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
GNAS R201H Complete Match JAK inhibitor Responsive CANCER Pre-clinical
U2AF1 S34F Complete Match FLT3 inhibitor Responsive CANCER Pre-clinical
TP53 C275F Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 C275F Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 C275F Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 C275F Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 C275F Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 C275F Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C275F Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C275F Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C275F Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 C275F Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 C275F Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 C275F Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C275F Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 C275F Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C275F Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 M246R Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 M246R Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 M246R Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 M246R Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 M246R Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 M246R Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 M246R Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 M246R Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 M246R Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 M246R Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 M246R Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 M246R Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 M246R Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 M246R Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 M246R Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C135Y Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 C135Y Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 C135Y Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 C135Y Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 C135Y Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 C135Y Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C135Y Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C135Y Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C135Y Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 C135Y Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 C135Y Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 C135Y Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C135Y Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 C135Y Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C135Y Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P151T Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 P151T Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 P151T Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 P151T Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 P151T Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 P151T Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P151T Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P151T Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P151T Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 P151T Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 P151T Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 P151T Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P151T Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 P151T Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P151T Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S127F Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 S127F Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 S127F Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 S127F Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 S127F Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 S127F Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S127F Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S127F Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S127F Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 S127F Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 S127F Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 S127F Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S127F Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 S127F Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S127F Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
CDKN2A R58* Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A R58* Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A R58* Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A R58* Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A R58* Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A R58* Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A R58* Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A R58* Different Alteration CDK4/6 inhibitor Responsive CM Case report
CDKN2A N42I Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A N42I Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A N42I Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A N42I Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A N42I Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A N42I Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A N42I Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A N42I Different Alteration CDK4/6 inhibitor Responsive CM Case report
PBRM1 splice_acceptor_variant Different Alteration Everolimus (MTOR inhibitor) Responsive R Pre-clinical
PBRM1 splice_acceptor_variant Complete Match anti-PD1 inhibitor Responsive RCCC Early trials
PBRM1 splice_acceptor_variant Complete Match Everolimus (MTOR inhibitor) Responsive RCC Early trials
PBRM1 splice_acceptor_variant Complete Match EZH2 inhibitor Responsive CANCER Pre-clinical
PBRM1 splice_acceptor_variant Different Alteration EZH2 inhibitor Responsive CANCER Pre-clinical
BRD4 5-UTRSNV Different Alteration BET inhibitor Responsive NMC Case report
TP53 I255T Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 I255T Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 I255T Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 I255T Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 I255T Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 I255T Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 I255T Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 I255T Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 I255T Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 I255T Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 I255T Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 I255T Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 I255T Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 I255T Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 I255T Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
RAD51C splice_acceptor_variant Complete Match PARP inhibitor Responsive OV Early trials
MET H542H Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
NTRK3 A435S), NTRK3 MUT* (R645C Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 A435S), NTRK3 MUT* (R645C Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 A435S), NTRK3 MUT* (R645C Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
BRD4 R10I Different Alteration BET inhibitor Responsive NMC Case report
ROS1 V785M Different Alteration Crizotinib (ALK inhibitor) Responsive IM Case report
ROS1 V785M Different Alteration Crizotinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ROS1 V785M Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Case report
ROS1 V785M Different Alteration HSP90 inhibitor Responsive LUAD Pre-clinical
ROS1 V785M Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Early trials
NOTCH2 G1000G Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
ERBB4 R196C Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
ALK R200K Different Alteration ALK inhibitor;SRC inhibitor Responsive LUAD Pre-clinical
ALK R200K Different Alteration Crizotinib (ALK inhibitor) Responsive GB, LY Early trials
ALK R200K Different Alteration Lorlatinib (ALK&ROS1 inhibitor) Responsive NSCLC Early trials
ALK R200K Different Alteration Crizotinib (ALK inhibitor) Responsive THCA, IM Case report
ALK R200K Different Alteration HSP90 inhibitor Responsive LUAD Early trials
ALK R200K Different Alteration Ceritinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK R200K Different Alteration Ceritinib (ALK inhibitor) Responsive IM, COREAD Case report
ALK R200K Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK R200K Different Alteration Brigatinib (Pan-TK inhibitor) Responsive NSCLC FDA guidelines
ALK R200K Different Alteration Entrictinib (Pan-TK inhibitor) Responsive COREAD Case report
ALK R200K Different Alteration Alectinib (ALK inhibitor) Responsive LUAD FDA guidelines
ALK R200K Different Alteration HSP90 inhibitor (HSP90 inhibitor) Responsive LUAD Early trials
ALK R200K Different Alteration ALK inhibitor;IGF1R inhibitor Responsive LUAD Pre-clinical
ALK R200K Different Alteration ALK inhibitor;MEK inhibitor Responsive LUAD Pre-clinical
ALK R200K Different Alteration novel ALK inhibitor Responsive LUAD Early trials
ALK R200K Different Alteration Ceritinib (ALK inhibitor) Responsive HEMATO Early trials
ALK R200K Different Alteration ALK inhibitor Responsive COREAD Case report
ALK R200K Different Alteration Alectinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ALK R200K Different Alteration MEK inhibitor (ALK inhibitor;MEK inhibitor) Responsive LUAD Pre-clinical
MET M118L Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
KMT2A Q2575Q Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A Q2575Q Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A Q2575Q Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A Q2575Q Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A Q2575Q Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A Q2575Q Different Alteration DOT1L inhibitor Responsive AML Early trials
NOTCH2 3-UTRSNV Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
NOTCH1 A1707T Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 A1707T Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
BRD4 G691S Different Alteration BET inhibitor Responsive NMC Case report
ERBB4 E1144* Different Mutation Lapatinib (ERBB2 inhibitor) Responsive CM Pre-clinical
ERBB4 E1144* Different Mutation ERBB2 inhibitor Resistant BRCA Case report
ERBB4 E1144* Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
EGFR R669* Different Alteration Erlotinib (EGFR inhibitor) Responsive L Case report
EGFR R669* Different Alteration Erlotinib (EGFR inhibitor) Responsive NSCLC Case report
PDGFRA A1014T Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive MDPS, MDS, ECL, HES FDA guidelines
FGFR3 V700A Different Alteration FGFR inhibitor Responsive BLCA Case report
FGFR3 V700A Different Alteration FGFR inhibitor Responsive G Early trials
FGFR3 V700A Different Alteration FGFR inhibitor Responsive NSCLC Pre-clinical
MET P1078S Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
BRD4 S662S Different Alteration BET inhibitor Responsive NMC Case report
FAT1 G3103* Complete Match BET inhibitor Responsive HNSC Pre-clinical
ROS1 K2307N Different Alteration Crizotinib (ALK inhibitor) Responsive IM Case report
ROS1 K2307N Different Alteration Crizotinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ROS1 K2307N Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Case report
ROS1 K2307N Different Alteration HSP90 inhibitor Responsive LUAD Pre-clinical
ROS1 K2307N Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Early trials
NTRK1 T734M Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Case report
NTRK1 T734M Different Alteration Pan-TKR inhibitor Responsive CANCER Early trials
NTRK1 T734M Different Alteration Pan-TK inhibitor Responsive LUAD Pre-clinical
NTRK1 T734M Different Alteration Pan-TK inhibitor Responsive COREAD Case report
BRD4 S1221S Different Alteration BET inhibitor Responsive NMC Case report
ROS1 Y228Y Different Alteration Crizotinib (ALK inhibitor) Responsive IM Case report
ROS1 Y228Y Different Alteration Crizotinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ROS1 Y228Y Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Case report
ROS1 Y228Y Different Alteration HSP90 inhibitor Responsive LUAD Pre-clinical
ROS1 Y228Y Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Early trials
MSH2 splice_acceptor_variant Complete Match PD1/PDL1 inhibitor Responsive UTH Early trials
MSH2 splice_acceptor_variant Different Alteration PD1/PDL1 inhibitor Responsive UTH Early trials
KMT2A F1405F Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A F1405F Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A F1405F Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A F1405F Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A F1405F Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A F1405F Different Alteration DOT1L inhibitor Responsive AML Early trials
RET A756D), RET MUT* (F329L Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET A756D), RET MUT* (F329L Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET A756D), RET MUT* (F329L Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET A756D), RET MUT* (F329L Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET A756D), RET MUT* (F329L Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET A756D), RET MUT* (F329L Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET A756D), RET MUT* (F329L Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET A756D), RET MUT* (F329L Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET A756D), RET MUT* (F329L Different Alteration RET inhibitor Responsive TH Pre-clinical
NRG1 N515S), NRG1 MUT* (R220H Different Alteration Lapatinib (ERBB2 inhibitor) Responsive LUAD Pre-clinical
NRG1 N515S), NRG1 MUT* (R220H Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Case report
ROS1 W21* Different Alteration Crizotinib (ALK inhibitor) Responsive IM Case report
ROS1 W21* Different Alteration Crizotinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ROS1 W21* Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Case report
ROS1 W21* Different Alteration HSP90 inhibitor Responsive LUAD Pre-clinical
ROS1 W21* Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Early trials
NTRK3 P48P Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 P48P Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 P48P Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
NOTCH1 P1884P Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 P1884P Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
AKT3 5-UTRSNV Different Alteration ATP competitive AKT inhibitor Responsive BRCA Pre-clinical
MET L982M Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
MSH3 R734* Complete Match DNA-PKc inhibitor Responsive CANCER Pre-clinical
NOTCH1 C833Y Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 C833Y Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
ERBB4 A672D Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
ABL1 A1038V Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
ABL1 A1038V Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
ABL1 A1038V Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
ABL1 A1038V Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
ABL1 A1038V Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
ABL1 A1038V Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
SMARCA4 R978* Complete Match EZH2 inhibitor Responsive OVRT Case report
SMARCA4 R978* Complete Match AURKA inhibitor Responsive NSCLC Pre-clinical
SMARCA4 R978* Complete Match EZH2 inhibitor Responsive OV Case report
SMARCA4 R978* Different Alteration EZH2 inhibitor Responsive OVRT Case report
SMARCA4 R978* Different Alteration EZH2 inhibitor Responsive OV Case report
NOTCH1 D469Y Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 D469Y Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
ESR1 R477L Different Alteration ESR1 inhibitor Resistant BRCA Pre-clinical
ERBB4 D1009D), ERBB4 MUT* (N1044D Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
PML H544Y Different Alteration Volasertib (PLK1 inhibitor) Responsive AML Early trials
PML H544Y Different Alteration Tretinoin (Retinoid) Responsive APML FDA guidelines
PML H544Y Different Alteration Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) Responsive AML FDA guidelines
FGFR3 V356V Different Alteration FGFR inhibitor Responsive BLCA Case report
FGFR3 V356V Different Alteration FGFR inhibitor Responsive G Early trials
FGFR3 V356V Different Alteration FGFR inhibitor Responsive NSCLC Pre-clinical
KMT2A D2298N Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A D2298N Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A D2298N Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A D2298N Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A D2298N Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A D2298N Different Alteration DOT1L inhibitor Responsive AML Early trials
NOTCH1 A585T Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 A585T Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
ABL1 A487D), ABL1 MUT* (P131S Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
ABL1 A487D), ABL1 MUT* (P131S Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
ABL1 A487D), ABL1 MUT* (P131S Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
ABL1 A487D), ABL1 MUT* (P131S Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
ABL1 A487D), ABL1 MUT* (P131S Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
ABL1 A487D), ABL1 MUT* (P131S Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
SMARCA1 E1037* Complete Match EZH2 inhibitor Responsive CANCER Pre-clinical
FGFR3 Q547Q Different Alteration FGFR inhibitor Responsive BLCA Case report
FGFR3 Q547Q Different Alteration FGFR inhibitor Responsive G Early trials
FGFR3 Q547Q Different Alteration FGFR inhibitor Responsive NSCLC Pre-clinical
NTRK3 intron_variant Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
ERBB2 V842I Different Alteration Pertuzumab (ERBB2 mAb inhibitor) Responsive BRCA FDA guidelines
ERBB2 V842I Different Alteration Lapatinib (ERBB2 inhibitor) Responsive BRCA FDA guidelines
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive ST, BRCA, GEJA FDA guidelines
ERBB2 V842I Different Alteration Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) Responsive BRCA FDA guidelines
ERBB2 V842I Different Alteration MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) Responsive SOLID Early trials
ERBB2 V842I Complete Match Lapatinib (ERBB2 inhibitor) Responsive BRCA Pre-clinical
ERBB2 V842I Complete Match Neratinib (ERBB2 inhibitor) Responsive BRCA Pre-clinical
ERBB2 V842I Different Mutation Trastuzumab (ERBB2 mAb inhibitor) Responsive CANCER, BRCA Pre-clinical
ERBB2 V842I Complete Match Neratinib (ERBB2 inhibitor) Responsive CANCER Early trials
ERBB2 V842I Different Mutation Neratinib (ERBB2 inhibitor) Responsive CANCER Early trials
ERBB2 V842I Different Mutation Neratinib (ERBB2 inhibitor) Responsive BRCA Case report
ERBB2 V842I Different Mutation Lapatinib (ERBB2 inhibitor) Responsive BRCA, LUAD Case report
ERBB2 V842I Different Mutation Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) Responsive L Early trials
ERBB2 V842I Different Mutation Neratinib (ERBB2 inhibitor) Resistant BRCA Case report
ERBB2 V842I Different Mutation Afatinib (ERBB2 & EGFR inhibitor) Responsive BRCA Pre-clinical
ERBB2 V842I Different Mutation Trastuzumab (ERBB2 mAb inhibitor) Responsive LUAD Case report
ERBB2 V842I Different Mutation Neratinib (ERBB2 inhibitor) Responsive BRCA Pre-clinical
ERBB2 V842I Different Mutation Lapatinib (ERBB2 inhibitor) Resistant BRCA Pre-clinical
ERBB2 V842I Different Mutation Trastuzumab (ERBB2 mAb inhibitor) Responsive CANCER Pre-clinical
ERBB2 V842I Complete Match Temsirolimus (MTOR inhibitor) Responsive LUAD Early trials
ERBB2 V842I Complete Match Dacomitinib (Pan ERBB inhibitor) Responsive NSCLC Early trials
ERBB2 V842I Complete Match Neratinib (ERBB2 inhibitor) Responsive LUAD Early trials
ERBB2 V842I Different Mutation ERBB2 inhibitor Responsive LUAD Early trials
ERBB2 V842I Different Mutation Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Early trials
ERBB2 V842I Different Mutation ERBB2 mAb inhibitor Responsive LUAD Early trials
ERBB2 V842I Different Mutation Neratinib (ERBB2 inhibitor) Responsive LUAD Early trials
ERBB2 V842I Different Mutation Lapatinib (ERBB2 inhibitor) Responsive LUAD Early trials
ERBB2 V842I Different Mutation Trastuzumab (ERBB2 mAb inhibitor) Responsive LUAD Early trials
ERBB2 V842I Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive BRCA Late trials
ERBB2 V842I Different Alteration Pertuzumab (ERBB2 mAb inhibitor) Responsive BT Early trials
ERBB2 V842I Different Alteration Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Responsive COREAD Late trials
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive OV Early trials
ERBB2 V842I Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive BLCA Case report
ERBB2 V842I Different Alteration Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) Responsive COREAD Case report
ERBB2 V842I Different Alteration Rociletinib (EGFR inhibitor) Resistant LUAD Case report
ERBB2 V842I Different Alteration Osimertinib (EGFR inhibitor) Resistant LUAD Case report
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive BT Early trials
ERBB2 V842I Different Alteration EGFR mAb inhibitor Resistant COREAD Early trials
ERBB2 V842I Different Alteration Lapatinib (ERBB2 inhibitor) Responsive BT Early trials
ERBB2 V842I Different Alteration Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) Responsive BRCA Early trials
ERBB2 V842I Different Alteration HER2 inhibitor;CDK4/6 inhibitor Responsive BRCA Pre-clinical
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive BRCA FDA guidelines
ERBB2 V842I Different Alteration Pertuzumab (ERBB2 mAb inhibitor) Responsive ST Early trials
ERBB2 V842I Different Alteration Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) Responsive BRCA Early trials
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive ST, GEJA FDA guidelines
ERBB2 V842I Different Alteration ERBB2 inhibitor;CDK4/6 inhibitor Responsive BRCA Pre-clinical
ERBB2 V842I Different Alteration Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) Responsive BRCA FDA guidelines
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive HNC Case report
ERBB2 V842I Different Alteration Neratinib (ERBB2 inhibitor) Responsive BRCA Late trials
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) No Responsive ED Early trials
ERBB2 V842I Different Alteration Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Responsive ED Pre-clinical
ERBB2 V842I Different Alteration Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) Responsive ST Early trials
ERBB2 V842I Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive ST Case report
ERBB2 V842I Different Alteration EGFR inhibitor Resistant LUAD Pre-clinical
PDGFRA 3-UTRSNV Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive MDPS, MDS, ECL, HES FDA guidelines
RET R770* Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET R770* Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET R770* Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET R770* Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET R770* Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET R770* Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET R770* Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET R770* Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET R770* Different Alteration RET inhibitor Responsive TH Pre-clinical
ROS1 Q617H Different Alteration Crizotinib (ALK inhibitor) Responsive IM Case report
ROS1 Q617H Different Alteration Crizotinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ROS1 Q617H Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Case report
ROS1 Q617H Different Alteration HSP90 inhibitor Responsive LUAD Pre-clinical
ROS1 Q617H Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Early trials
NRG1 L77L Different Alteration Lapatinib (ERBB2 inhibitor) Responsive LUAD Pre-clinical
NRG1 L77L Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Case report
ERBB4 D991D Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
FANCA splice_acceptor_variant Complete Match Olaparib (PARP inhibitor) Responsive PRAD Case report
FANCA splice_acceptor_variant Different Alteration Olaparib (PARP inhibitor) Responsive PRAD Case report
MET C818C Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
NOTCH2 S613I), NOTCH2 MUT* (A1599D Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
ABL1 3-UTRSNV Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
ABL1 3-UTRSNV Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
ABL1 3-UTRSNV Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
ABL1 3-UTRSNV Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
ABL1 3-UTRSNV Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
ABL1 3-UTRSNV Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
RET P1070S Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET P1070S Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET P1070S Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET P1070S Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET P1070S Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET P1070S Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET P1070S Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET P1070S Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET P1070S Different Alteration RET inhibitor Responsive TH Pre-clinical
BRD4 S717S Different Alteration BET inhibitor Responsive NMC Case report
ARID1A Q920* Complete Match EZH2 inhibitor Responsive OV Pre-clinical
ARID1A Q920* Complete Match PD1 inhibitor Responsive OV Pre-clinical
ARID1A Q920* Complete Match PARP inhibitor Responsive CANCER Pre-clinical
ARID1A Q920* Complete Match ATR inhibitor Responsive CANCER Pre-clinical
JAK2 R443* Different Alteration Ruxolitinib (JAK inhibitor) Responsive ALL Pre-clinical
PDGFRA R522H Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive MDPS, MDS, ECL, HES FDA guidelines
NTRK3 R791W Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 R791W Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 R791W Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
NOTCH2 Q2389Q Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
NOTCH1 A2101T Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 A2101T Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
POLE splice_donor_variant Complete Match PD1/PDL1 inhibitor Responsive UTH Early trials
POLE splice_donor_variant Complete Match PD1 Ab inhibitor Responsive COREAD Case report
POLE splice_donor_variant Different Mutation PD1 Ab inhibitor Responsive G, ED Case report
POLE splice_donor_variant Different Alteration PD1/PDL1 inhibitor Responsive UTH Early trials
ABL1 L599F Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
ABL1 L599F Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
ABL1 L599F Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
ABL1 L599F Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
ABL1 L599F Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
ABL1 L599F Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
FAT1 splice_acceptor_variant Complete Match BET inhibitor Responsive HNSC Pre-clinical
RET R57W Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET R57W Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET R57W Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET R57W Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET R57W Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET R57W Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET R57W Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET R57W Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET R57W Different Alteration RET inhibitor Responsive TH Pre-clinical
EPHA2 C369* Different Mutation MTOR inhibitor Responsive LUSC Pre-clinical
EPHA2 C369* Different Mutation Dasatinib (BCR-ABL inhibitor) Responsive LUSC Pre-clinical
EPHA2 C369* Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive CANCER Pre-clinical
ERBB4 P697S Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
EGFR D800G Different Alteration Erlotinib (EGFR inhibitor) Responsive L Case report
EGFR D800G Different Alteration Erlotinib (EGFR inhibitor) Responsive NSCLC Case report
JAK2 S602I Different Alteration Ruxolitinib (JAK inhibitor) Responsive ALL Pre-clinical
RAF1 R618R Different Alteration Sorafenib (Pan-TK inhibitor) Responsive PRAD Pre-clinical
RAF1 R618R Different Alteration Pan-RAF inhibitor Responsive PRAD Pre-clinical
RAF1 R618R Different Alteration U0126 (MEK inhibitor) Responsive PRAD Pre-clinical
MET P295H Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
FGFR3 D318N Different Alteration FGFR inhibitor Responsive BLCA Case report
FGFR3 D318N Different Alteration FGFR inhibitor Responsive G Early trials
FGFR3 D318N Different Alteration FGFR inhibitor Responsive NSCLC Pre-clinical
DDR2 G505S Different Mutation Erlotinib (EGFR inhibitor) Responsive LUSC Case report
DDR2 G505S Different Mutation Dasatinib (BCR-ABL inhibitor) Responsive LUSC Case report
DDR2 G505S Complete Match Dasatinib (BCR-ABL inhibitor) Responsive LUSC Pre-clinical
RET R844W Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET R844W Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET R844W Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET R844W Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET R844W Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET R844W Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET R844W Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET R844W Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET R844W Different Alteration RET inhibitor Responsive TH Pre-clinical
NRG1 R490M Different Alteration Lapatinib (ERBB2 inhibitor) Responsive LUAD Pre-clinical
NRG1 R490M Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Case report
TP53 R282W Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R282W Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R282W Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R282W Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R282W Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R282W Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R282W Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R282W Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R282W Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R282W Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R282W Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R282W Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R282W Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R282W Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R282W Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
KRAS G12C Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12C Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12C Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12C Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12C Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12C Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12C Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12C Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12C Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12C Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12C Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12C Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12C Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12C Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12C Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12C Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12C Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12C Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12C Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12C Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12C Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12C Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12C Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12C Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12C Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12C Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12C Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12C Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12C Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12C Complete Match FAS inhibitor Responsive L Case report
KRAS G12C Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12C Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12C Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12C Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12C Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12C Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12C Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12C Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12C Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12C Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 S215G Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 S215G Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 S215G Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 S215G Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 S215G Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 S215G Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S215G Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S215G Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S215G Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 S215G Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 S215G Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 S215G Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S215G Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 S215G Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S215G Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Q192* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Q192* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Q192* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Q192* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Q192* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Q192* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Q192* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Q192* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Q192* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Q192* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Q192* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Q192* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Q192* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Q192* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Q192* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
RET R57Q Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET R57Q Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET R57Q Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET R57Q Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET R57Q Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET R57Q Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET R57Q Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET R57Q Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET R57Q Different Alteration RET inhibitor Responsive TH Pre-clinical
TP53 E298* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 E298* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 E298* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 E298* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 E298* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 E298* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 E298* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E298* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E298* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 E298* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 E298* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 E298* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E298* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 E298* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E298* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G199* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G199* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G199* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G199* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G199* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G199* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G199* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G199* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G199* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G199* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G199* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G199* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G199* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G199* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G199* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G245V Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G245V Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G245V Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G245V Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G245V Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G245V Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G245V Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G245V Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G245V Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G245V Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G245V Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G245V Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G245V Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G245V Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G245V Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NTRK1 R702C Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Case report
NTRK1 R702C Different Alteration Pan-TKR inhibitor Responsive CANCER Early trials
NTRK1 R702C Different Alteration Pan-TK inhibitor Responsive LUAD Pre-clinical
NTRK1 R702C Different Alteration Pan-TK inhibitor Responsive COREAD Case report
TP53 I254S Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 I254S Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 I254S Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 I254S Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 I254S Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 I254S Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 I254S Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 I254S Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 I254S Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 I254S Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 I254S Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 I254S Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 I254S Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 I254S Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 I254S Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
CDKN2A E88* Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A E88* Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A E88* Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A E88* Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A E88* Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A E88* Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A E88* Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A E88* Different Alteration CDK4/6 inhibitor Responsive CM Case report
LRP1B R2240* Complete Match Liposomal Doxorubicin (Chemotherapy) Resistant OV Early trials
LRP1B R2240* Different Alteration Liposomal Doxorubicin (Chemotherapy) Resistant OV Early trials
ERCC4 Q65* Complete Match Cisplatin (Chemotherapy) Responsive OV Pre-clinical
TP53 S241F Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 S241F Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 S241F Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 S241F Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 S241F Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 S241F Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S241F Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S241F Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S241F Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 S241F Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 S241F Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 S241F Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S241F Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 S241F Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S241F Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
SF3B1 G740E Different Mutation Spliceosome inhibitor Responsive CANCER Pre-clinical
TP53 P250L Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 P250L Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 P250L Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 P250L Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 P250L Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 P250L Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P250L Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P250L Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P250L Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 P250L Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 P250L Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 P250L Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P250L Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 P250L Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P250L Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R337C Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R337C Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R337C Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R337C Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R337C Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R337C Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R337C Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R337C Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R337C Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R337C Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R337C Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R337C Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R337C Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R337C Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R337C Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
CTNNB1 T41A Different Mutation Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) Responsive ED Early trials
CTNNB1 T41A Complete Match Tankyrase inhibitor Resistant COREAD Pre-clinical
TP53 V274F Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 V274F Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 V274F Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 V274F Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 V274F Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 V274F Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V274F Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V274F Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V274F Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 V274F Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 V274F Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 V274F Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V274F Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 V274F Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V274F Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R306* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R306* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R306* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R306* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R306* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R306* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R306* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R306* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R306* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R306* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R306* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R306* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R306* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R306* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R306* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NOTCH1 C449C Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 C449C Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
TP53 L194H Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 L194H Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 L194H Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 L194H Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 L194H Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 L194H Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 L194H Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 L194H Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 L194H Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 L194H Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 L194H Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 L194H Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 L194H Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 L194H Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 L194H Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
PIK3CA M1043L Different Mutation BRAF inhibitor Resistant CM Case report
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive BLCA, HNC Case report
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive HNSC Case report
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive G, THCA Pre-clinical
PIK3CA M1043L Complete Match Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) Responsive BRCA Late trials
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive COREAD Pre-clinical
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive ED, OV, CESC Early trials
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive BRCA Late trials
PIK3CA M1043L Complete Match PIK3CA inhibitor Responsive BRCA Early trials
PIK3CA M1043L Complete Match PIK3CA inhibitor Responsive ST Case report
PIK3CA M1043L Complete Match AKT inhibitor Responsive BRCA Early trials
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive;Responsive L Pre-clinical;Case report
PIK3CA M1043L Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
PIK3CA M1043L Different Alteration PI3K pathway inhibitor Resistant BRCA Pre-clinical
TP53 E286* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 E286* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 E286* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 E286* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 E286* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 E286* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 E286* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E286* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E286* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 E286* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 E286* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 E286* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E286* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 E286* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E286* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ATM L1347* Different Mutation AZD6738 (ATR inhibitor) Responsive BCL Early trials
ATM L1347* Complete Match Cisplatin (Chemotherapy) Responsive BLCA Early trials
ATM L1347* Complete Match Olaparib (PARP inhibitor) Responsive ST, PRAD Early trials
ATM L1347* Complete Match PARP inhibitor Responsive ST Early trials
ATM L1347* Complete Match ATR inhibitor Responsive COREAD Case report
ATM L1347* Complete Match DNA-PKc inhibitor Responsive LY Pre-clinical
ATM L1347* Complete Match Temozolomide (Chemotherapy) Responsive G Pre-clinical
ATM L1347* Complete Match PD1/PDL1 inhibitor Responsive UTH Early trials
ATM L1347* Different Alteration PD1/PDL1 inhibitor Responsive UTH Early trials
ATM L1347* Different Alteration DNA-PKc inhibitor Responsive LY Pre-clinical
ATM L1347* Different Alteration PARP inhibitor Responsive ST Early trials
ATM L1347* Different Alteration ATR inhibitor Responsive COREAD Case report
ATM L1347* Different Alteration Cisplatin (Chemotherapy) Responsive BLCA Early trials
KMT2A R442Q Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A R442Q Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A R442Q Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A R442Q Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A R442Q Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A R442Q Different Alteration DOT1L inhibitor Responsive AML Early trials
PLCG2 K539* Different Mutation Ibrutinib (BTK inhibitor) Resistant CLL Early trials
CDKN2A Q50* Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A Q50* Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A Q50* Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A Q50* Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A Q50* Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A Q50* Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A Q50* Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A Q50* Different Alteration CDK4/6 inhibitor Responsive CM Case report
TP53 G154V Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G154V Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G154V Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G154V Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G154V Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G154V Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G154V Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G154V Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G154V Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G154V Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G154V Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G154V Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G154V Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G154V Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G154V Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ARID1A Q1277* Complete Match EZH2 inhibitor Responsive OV Pre-clinical
ARID1A Q1277* Complete Match PD1 inhibitor Responsive OV Pre-clinical
ARID1A Q1277* Complete Match PARP inhibitor Responsive CANCER Pre-clinical
ARID1A Q1277* Complete Match ATR inhibitor Responsive CANCER Pre-clinical
TP53 N239D Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 N239D Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 N239D Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 N239D Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 N239D Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 N239D Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 N239D Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 N239D Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 N239D Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 N239D Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 N239D Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 N239D Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 N239D Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 N239D Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 N239D Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
PBRM1 splice_donor_variant Different Alteration Everolimus (MTOR inhibitor) Responsive R Pre-clinical
PBRM1 splice_donor_variant Complete Match anti-PD1 inhibitor Responsive RCCC Early trials
PBRM1 splice_donor_variant Complete Match Everolimus (MTOR inhibitor) Responsive RCC Early trials
PBRM1 splice_donor_variant Complete Match EZH2 inhibitor Responsive CANCER Pre-clinical
PBRM1 splice_donor_variant Different Alteration EZH2 inhibitor Responsive CANCER Pre-clinical
Variation Gene Transcript Protein Alteration Consequence Tumour Driver Oncogenic Classification

Select a gene to see its drug/phenotype/protein interactions

Pathway ID Description Parent(s) p-Value Genes Involved

All significant pathways (p<0.05) in the selected cohort are presented in the Voronoi interactive plot, with colour intensity representing the number of patients affected
Click here to show visualisation below or here to open the visualisation in a new window

Principal component analyses (PCA) transforms the data into a coordinate system and presents it as an orthogonal projection. This allows for key “components” of variation in the data to be viewed with ease. Each point represents the orientation of a sample in the transcriptional space and each colour represents the origin of excision of the sample.

Scatterplot of Two main Principal Components

Scatterplot of Three main Principal Components

Loading...

Box Plot

Bar Plot

Correlations for user-defined genes are calculated using the Pearson Product Moment Correlation Coefficient (PMCC) value. An interactive heatmap of results is presented for each comparative group in the study.
Loading...
The relationship between molecular subtype/gene(s) of interest and survival can be assessed.
  • Molecular subtype: Each sample is assigned to a risk group according to molecular subtype designation.
  • Defined gene(s): A univariate model is applied to the survival data and samples are assigned to risk groups based on the median dichotomisation of mRNA expression intensities of the selected gene(s).
Kaplan Meier plots are generated for each gene and a summary of survival covariates are presented in tabular format.
Loading...

Researchers can request samples from PCRFTB to support their research activities.

*Based on your filtering criteria you can view the number of available patients and associated samples in PCRFTB

  • 700 patients with Blood, FFPE tissue, Fresh frozen samples are available from PCRFTB.

    • In order to apply for samples, please use the PCRFTB Tissue Request System to submit an Expression of interest.

    For more details about the PCRFTB Application workflow please visit the PCRFTB website.

    If you require further details please contact us enquiries@thepancreastissuebank.org

    Please visit Tissue Bank